ALKS — Alkermes Plc

Alkermes Plc (ALKS) is a drug manufacturers - specialty & generic company listed on NASDAQ. It is led by Richard F. Pops, based in Connaught House, Dublin, Ireland, D04 C5Y6, with about 1,800 employees. Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

Latest reported ALKS revenue for 2025-09-30 was $394.2M. Net income was $192.3M. Revenue was up 0.9% from 2025-06-30 to 2025-09-30. ALKS currently screens at market cap $4.78B and trailing P/E 13.8.

Use this ALKS page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the ALKS quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the ALKS SEC filings page. Lician reads the product cache first so this HTML stays unique to Alkermes Plc even when a live quote feed is slow.